Horizon Scanning in Oncology: Results of the 27th Prioritisation – 2nd quarter 2016 by Grössmann, N. & Wild, C.
Horizon Scanning in Oncology    
 
Ergänzende Informationen zu den Arzneistoffen für Priorisierung XXVII – HSS Onkologie Seite 1 von 12 
 
 
 
 
 
Horizon Scanning in Oncology 
27
th
 Prioritization –  2nd quarter 2016 
 
General Information, efficacy and 
safety data 
 
 
 
 
 
 
Nicole Grössmann 
Claudia Wild 
 
 
 
Please note: 
Within this document you find general information about the drug of interest and the indication it is 
intended to be used for. Further we have included full text publications and conference abstracts of 
phase III trials, assessing the safety and efficacy of the drugs of interest. 
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Introduction 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), 9 information sources are scanned 
frequently to identify emerging anticancer drugs. 
Every 3 months, these anticancer therapies are filtered (i.e. in most cases defined as availability of 
phase III results; for orphan drugs also phase II) to identify drugs at/around the same time as the 
accompanying drug licensing decisions of the EMA.  
An expert panel consisting of oncologists and pharmacists then applies 5 prioritisation criteria to 
elicit those anti-cancer therapies which might be associated with either a considerable impact on 
financial resources or a substantial health benefit.  
For the 27
th
 prioritisation (June 2016), 12 drugs were filtered out of 282 identified and were sent to 
prioritisation. Of these, 5 drugs were ranked as ‘highly relevant’ by the expert panel, 7 as ‘relevant’ 
and none as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for example, 
abstracts of phase III studies and licensing status is contained in this document. 
The summary judgements of the expert panel for all prioritised drugs are provided in the following 
table. 
 
No Filtered Drugs – 27th prioritisation 2nd quarter 2016 
Overall 
category 
1. 
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan 
alone as second-line treatment for patients with sensitive relapsed small-cell lung 
cancer 
Relevant 
2. 
Erlotinib (Tarceva
®
) alone or with bevacizumab (Avastin
®
) as first-line therapy in patients 
with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations 
Relevant 
3. 
Oral ixazomib (MLN9708, Ninlaro
®
), lenalidomide, and dexamethasone for multiple 
myeloma 
Highly 
relevant 
4. 
Phase III trial evaluating letrozole (Femara
®
) as first-line endocrine therapy with or 
without bevacizumab (Avastin
®
) for the treatment of postmenopausal women with 
hormone receptor–positive advanced-stage breast cancer 
Relevant 
5. 
Fulvestrant plus palbociclib (Ibrance
®
) versus fulvestrant plus placebo for treatment of 
hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on 
previous endocrine therapy 
Relevant 
6. 
Atezolizumab (Tecentriq
®
) in patients with locally advanced and metastatic urothelial 
carcinoma who have progressed following treatment with platinum-based chemotherapy 
Highly 
relevant 
7. 
Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men 
with metastatic castration-resistant prostate cancer 
Relevant 
8. 
Lenvatinib (Lenvima
®
), everolimus (Afinitor
®
), and the combination in patients with 
metastatic renal cell carcinoma 
Relevant 
9. 
Nivolumab (Opdivo
®
) in classical Hodgkin lymphoma after autologous stem cell 
transplant and brentuximab vedotin 
Highly 
relevant 
10. 
Brentuximab vedotin (Adcetris
®
) as consolidation therapy after autologous stem-cell 
transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression 
(AETHERA) 
Relevant 
11. 
Venetoclax (Venclexta™) in relapsed or refractory chronic lymphocytic leukaemia with 
17p deletion 
Highly 
relevant 
12. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia 
Highly 
relevant 
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1 Multiple Myeloma 
1.1 Oral ixazomib (MLN9708, Ninlaro®), lenalidomide, and 
dexamethasone for multiple myeloma 
Overview 
Drug Description 
is a reversible proteasome inhibitor that preferentially binds and inhibits 
the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome 
Patient Indication 
ixazomib plus lenalidomide–dexamethasone for relapsed, refractory, or 
relapsed and refractory multiple myeloma 
Incidence in 
Austria 
627 newly diagnosed per year (2012), 5.6 /100,000/year 
Ongoing Phase III NCT01564537 - until 05/2019 
Approval 
status for 
this 
indication 
EMA 
On 26 May 2016, the Committee for Medicinal Products for Human Use 
(CHMP) adopted a negative opinion, recommending the refusal of the 
marketing authorisation for the medicinal product Ninlaro, intended for the 
treatment of multiple myeloma.  Update of 24 June 2016: The company 
that applied for a marketing authorisation for Ninlaro has requested a re-
examination of the CHMP’s May 2016 opinion. Upon receipt of the 
grounds of the request, the CHMP will re-examine its opinion and issue a 
final recommendation. 
FDA 
11/2015: for the treatment of patients with multiple 
myeloma who have received at least one prior therapy 
Approval 
status for 
other 
indications 
EMA 
Ninlaro was designated an ‘orphan medicine’ on 27 September 2011, for 
the treatment of multiple myeloma. 
FDA 
01/2005: approved for the treatment of breast cancer after failure of 
combination chemotherapy for metastatic disease or relapse within 6 
months of adjuvant chemotherapy. Prior therapy should have included an 
anthracycline unless clinically contraindicated.  
09/2013: approved for metastatic adenocarcinoma of the pancreas as first-
line treatment, in combination with gemcitabine. 
 
10/2012: Locally advanced or metastatic Non-Small Cell Lung Cancer 
(NSCLC), as first-line treatment in combination with carboplatin, in patients 
who are not candidates for curative surgery or radiation therapy. 
Costs  - 
 
Phase III results  
NEJM (2016) 374:1621-1634 (Moreau et al.): “Oral Ixazomib, Lenalidomide, and Dexamethasone for 
Multiple Myeloma” 
Background 
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Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple 
myeloma. 
 
Methods 
In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 722 patients who had 
relapsed, refractory, or relapsed and refractory multiple myeloma to receive ixazomib plus 
lenalidomide–dexamethasone (ixazomib group) or placebo plus lenalidomide–dexamethasone 
(placebo group). The primary end point was progression-free survival. 
 
Results 
Progression-free survival was significantly longer in the ixazomib group than in the placebo group at a 
median follow-up of 14.7 months (median progression-free survival, 20.6 months vs. 14.7 months; 
hazard ratio for disease progression or death in the ixazomib group, 0.74; P=0.01); a benefit with 
respect to progression-free survival was observed with the ixazomib regimen, as compared with the 
placebo regimen, in all prespecified patient subgroups, including in patients with high-risk cytogenetic 
abnormalities. The overall rates of response were 78% in the ixazomib group and 72% in the placebo 
group, and the corresponding rates of complete response plus very good partial response were 48% 
and 39%. The median time to response was 1.1 months in the ixazomib group and 1.9 months in the 
placebo group, and the corresponding median duration of response was 20.5 months and 15.0 
months. At a median follow-up of approximately 23 months, the median overall survival has not been 
reached in either study group, and follow-up is ongoing. The rates of serious adverse events were 
similar in the two study groups (47% in the ixazomib group and 49% in the placebo group), as were 
the rates of death during the study period (4% and 6%, respectively); adverse events of at least grade 
3 severity occurred in 74% and 69% of the patients, respectively. Thrombocytopenia of grade 3 and 
grade 4 severity occurred more frequently in the ixazomib group (12% and 7% of the patients, 
respectively) than in the placebo group (5% and 4% of the patients, respectively). Rash occurred more 
frequently in the ixazomib group than in the placebo group (36% vs. 23% of the patients), as did 
gastrointestinal adverse events, which were predominantly low grade. The incidence of peripheral 
neuropathy was 27% in the ixazomib group and 22% in the placebo group (grade 3 events occurred in 
2% of the patients in each study group). Patient-reported quality of life was similar in the two study 
groups. 
 
Conclusions 
The addition of ixazomib to a regimen of lenalidomide and dexamethasone was associated with 
significantly longer progression-free survival; the additional toxic effects with this all-oral regimen were 
limited. (Funded by Millennium Pharmaceuticals; TOURMALINE-MM1 ClinicalTrials.gov number, 
NCT01564537.) 
2 Urothelial carcinoma 
2.1 Atezolizumab (Tecentriq®) in patients with locally advanced 
and metastatic urothelial carcinoma who have progressed 
following treatment with platinum-based chemotherapy 
 
Overview 
 
Drug Description a programmed death-ligand 1 (PD-L1) blocking antibody 
Patient Indication 
atezolizumab for metastatic urothelial carcinoma after failure of platinum-
based chemotherapy 
Incidence in 
Austria 
1,496 newly diagnosed per year (2012), 8.9 /100,000/year 
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Ongoing Phase III NCT02589717 - until 2016 
Approval 
status for 
this 
indication 
EMA - 
FDA 
05/2016: 
approved for the treatment of patients with locally advanced or metastatic 
urothelial carcinoma who:  
 have disease progression during or following platinum-containing 
chemotherapy. 
 have disease progression within 12 months of neoadjuvant or 
adjuvant treatment with platinum-containing chemotherapy. 
Approval 
status for 
other 
indications 
EMA - 
FDA - 
Costs - 
 
Phase II results  
The Lancet, Published Online March 4, 2016 (Rosenberg et al.): “Atezolizumab in patients with 
locally advanced and metastatic urothelial carcinoma who have progressed following treatment with 
platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial” 
Background 
Patients with metastatic urothelial carcinoma have few treatment options after failure of platinum-
based chemotherapy. In this trial, we assessed treatment with atezolizumab, an engineered 
humanised immunoglobulin G1 monoclonal antibody that binds selectively to programmed death 
ligand 1 (PD-L1), in this patient population. 
 
Methods 
For this multicentre, single-arm, two-cohort, phase 2 trial, patients (aged ≥18 years) with inoperable 
locally advanced or metastatic urothelial carcinoma whose disease had progressed after previous 
platinum-based chemotherapy were enrolled from 70 major academic medical centres and community 
oncology practices in Europe and North America. Key inclusion criteria for enrolment were Eastern 
Cooperative Oncology Group performance status of 0 or 1, measurable disease defined by Response 
Evaluation Criteria In Solid Tumours version 1.1 (RECIST v1.1), adequate haematological and end-
organ function, and no autoimmune disease or active infections. Formalin-fixed paraffin-embedded 
tumour specimens with sufficient viable tumour content were needed from all patients before 
enrolment. Patients received treatment with intravenous atezolizumab (1200 mg, given every 3 
weeks). PD-L1 expression on tumour-infiltrating immune cells (ICs) was assessed prospectively by 
immunohistochemistry. The co-primary endpoints were the independent review facility-assessed 
objective response rate according to RECIST v1.1 and the investigator-assessed objective response 
rate according to immune-modified RECIST, analysed by intention to treat. A hierarchical testing 
procedure was used to assess whether the objective response rate was significantly higher than the 
historical control rate of 10% at an α level of 0·05. This study is registered with ClinicalTrials.gov, 
number NCT02108652. 
 
Findings 
Between May 13, 2014, and Nov 19, 2014, 486 patients were screened and 315 patients were 
enrolled into the study. Of these patients, 310 received atezolizumab treatment (five enrolled patients 
later did not meet eligibility criteria and were not dosed with study drug). The PD-L1 expression status 
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on infiltrating immune cells (ICs) in the tumour microenvironment was defined by the percentage of 
PD-L1-positive immune cells: IC0 (<1%), IC1 (≥1% but <5%), and IC2/3 (≥5%). The primary analysis 
(data cut-off May 5, 2015) showed that compared with a historical control overall response rate of 
10%, treatment with atezolizumab resulted in a significantly improved RECIST v1.1 objective response 
rate for each prespecified immune cell group (IC2/3: 27% [95% CI 19–37], p<0·0001; IC1/2/3: 18% 
[13–24], p=0·0004) and in all patients (15% [11–20], p=0·0058). With longer follow-up (data cut-off 
Sept 14, 2015), by independent review, objective response rates were 26% (95% CI 18–36) in the 
IC2/3 group, 18% (13–24) in the IC1/2/3 group, and 15% (11–19) overall in all 310 patients. With a 
median follow-up of 11·7 months (95% CI 11·4–12·2), ongoing responses were recorded in 38 (84%) 
of 45 responders. Exploratory analyses showed The Cancer Genome Atlas (TCGA) subtypes and 
mutation load to be independently predictive for response to atezolizumab. Grade 3–4 treatment-
related adverse events, of which fatigue was the most common (five patients [2%]), occurred in 50 
(16%) of 310 treated patients. Grade 3–4 immune-mediated adverse events occurred in 15 (5%) of 
310 treated patients, with pneumonitis, increased aspartate aminotransferase, increased alanine 
aminotransferase, rash, and dyspnoea being the most common. No treatment-related deaths occurred 
during the study. 
 
Interpretation 
Atezolizumab showed durable activity and good tolerability in this patient population. Increased levels 
of PD-L1 expression on immune cells were associated with increased response. This report is the first 
to show the association of TCGA subtypes with response to immune checkpoint inhibition and to show 
the importance of mutation load as a biomarker of response to this class of agents in advanced 
urothelial carcinoma. 
3 Lymphoma 
3.1 Nivolumab (Opdivo®) in classical Hodgkin lymphoma after 
autologous stem cell transplant and brentuximab vedotin 
Overview 
Drug Description humanized IgG4 anti-PD-1 monoclonal antibody 
Patient Indication 
nivolumab for classical Hodgkin lymphoma (cHL) that has relapsed or 
progressed after autologous hematopoietic stem cell transplantation 
(HSCT) and post-transplantation brentuximab vedotin 
Incidence in 
Austria 
161 newly diagnosed per year (2012), 1.8/100,000/year 
Ongoing Phase III 
NCT02572167 - until 2020 
NCT01822509 - until 2016 
Approval 
status for 
this 
indication 
EMA - 
FDA 
On May 17, 2016 nivolumab received accelerated approval for the 
treatment of patients with classical Hodgkin lymphoma (cHL) that has 
relapsed or progressed after autologous hematopoietic stem cell 
transplantation (HSCT) and post-transplantation brentuximab vedotin. 
Based on the results of the CheckMate-205 and the CheckMate-039 trial. 
Approval 
status for 
other 
indications 
EMA 
05/2016: for the treatment of advanced melanoma as a monotherapy or in 
combination with ipilimumab 
 
02/2016: for the treatment of non-small cell lung cancer (NSCLC) that has 
spread locally or to other parts of the body in patients who have previously 
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been treated 
 
04/2016: as a monotherapy for advanced renal cell carcinoma in 
previously treated patients  
FDA 
09/2015: BRAF V600 wild-type unresectable or metastatic melanoma, as a 
single agent.  
09/2015: BRAF V600 mutation-positive unresectable or metastatic 
melanoma, as a single agent.  
09/2015: Unresectable or metastatic melanoma, in combination with 
ipilimumab. 
10/2015: Metastatic non-small cell lung cancer and progression on or after 
platinum based chemotherapy. Patients with EGFR or ALK genomic 
tumour aberrations should have disease progression on FDA-approved 
therapy for these aberrations prior to receiving OPDIVO.  
11/2015: Advanced renal cell carcinoma after prior anti-angiogenic 
therapy.  
Costs 
 nivolumab conc. 10mg/ml 40 ml €626; nivolumab conc. 10mg/ml 100 
ml: €1,517.50. 
The recommended dose-schedule of nivolumab is 3 mg/kg intravenously 
every 2 weeks until disease progression or unacceptable toxicity; 
assuming an average body weight of 70 kg, a dose of 210mg nivolumab 
would be needed, costing €3,186.75 per 2-week cycle and €6,373.5 per 
month. 
 
Abstracts 
ASCO 2016 Annual Meeting (Younes et al.) 
Background 
cHL is characterized by amplification at 9p24.1, causing overexpression of PD-1 ligands. Thus, cHL 
may be uniquely sensitive to PD-1 blockade. Nivo is a fully human IgG4 immune checkpoint inhibitor 
targeting PD-1 that showed promising results in a phase 1b study (NCT01592370) in pts with 
relapsed/refractory cHL (Ansell SM et al NEJM 2015;372:311–9), who currently have limited treatment 
options.  
 
Methods 
This study evaluated the efficacy and safety of nivo in pts with cHL who had received BV after failed 
ASCT, as Cohort B of the larger Phase 2 Checkmate 205 study (NCT02181738). Nivo was given at 3 
mg/kg IV q2w. Response was assessed by independent radiologic review committee (IRRC) and 
investigators (Inv), using 2007 IWG criteria. Primary endpoint was IRRC ORR.  
 
Results 
The main characteristics of 80 treated cHL pts were: median age 37 y, median (range) 4 prior 
regimens (3–15). 90% of pts had drug-related AEs: 25% G3–4, 1% G5 (multi-organ failure). Most 
common drug-related AEs were fatigue (25%), infusion reaction (IR; 20%) and rash (16%). Most 
common SAEs were pyrexia, tumour progression, arrhythmia, IR, septic meningitis, and pneumonia (≤ 
4% each). Select immune-related AEs, all G1–2, occurred in 26%. At database lock (DBL; October 
2015), median (range) follow-up was 8.9 mo (1.9–11.7). 64% of pts remained on therapy; main reason 
for discontinuation was disease progression (16%). IRRC ORR (95% CI) was 66% (54.8–76.4); CR 
and PR rates were 8.8% (3.6–17.2) and 57.5% (45.9–68.5), respectively. Inv ORR, a pre-specified 
secondary endpoint, was 73% (61.4–81.9); CR and PR rates were 27.5% (18.1–38.6) and 45.0% 
(33.8–56.5). 62% (33/53) of IRRC responders remained in response at DBL. 6 pts elected to stop nivo 
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and undergo stem cell transplant, all of these pts were alive at data cut-off. IRRC 6-mo PFS was 77%; 
OS was 99%. In 43 pts who had no prior BV response, nivo treatment resulted in an IRRC ORR of 
72% (31/43).  
 
Conclusions 
Nivo demonstrated a high response rate, long-lasting responses, and an acceptable safety profile in 
pts with cHL after ASCT and BV, including pts with no prior BV response. PFS and OS are 
encouraging in this heavily pre-treated population. Clinical trial information: NCT02181738 
 
 
2015 ASH 2015 Annual Meeting (Ansell et al.) 
Introduction 
The programmed death-1 (PD-1) immune checkpoint pathway regulates T-cell–mediated antitumor 
immune responses in solid tumours and hematologic malignancies. Nivolumab (Bristol-Myers Squibb, 
Ono Pharmaceutical) is a fully human IgG4 PD-1–blocking monoclonal antibody with demonstrated 
efficacy in a range of tumors. Results from an independent cohort of 23 pts with R/R cHL in a phase 1 
study (CA209-039) showed that nivolumab was well tolerated and yielded an overall response rate 
(ORR) of 87% (Ansell et al, N Engl J Med, 2015). This raises important questions including the 
necessary duration of treatment, the relevance of the depth of response (complete response [CR] vs 
partial response [PR]), the duration of response, and the feasibility of retreatment. Here, we present 
the clinical course and post-treatment outcomes from extended follow-up of these pts to shed some 
light on these questions. 
 
Methods 
Pts with R/R cHL received nivolumab 3 mg/kg at weeks (wks) 1 and 4, and then every 2 wks for up to 
2 years (yrs). Therapy was stopped earlier in pts with intolerance to treatment or progressive disease 
(PD) without evidence of clinical benefit. Pts who discontinued treatment due to toxicity were followed 
for up to 120 days after discontinuation; other pts were followed for 1 yr after discontinuation. 
Responding pts discontinued after confirmed CR or 16 wks after unconfirmed CR, or continued 
treatment for up to 2 yrs if they had PR or stable disease (SD). Pts who discontinued treatment with 
ongoing CR, PR, or SD could be retreated for confirmed PD occurring <1 yr after nivolumab 
discontinuation. Responses were evaluated using the Revised Response Criteria for Malignant 
Lymphoma (Cheson et al, J Clin Oncol, 2007). The primary endpoint was safety, and the key 
secondary endpoint was antitumor activity. 
 
Results 
A total of 23 pts with R/R cHL were treated. The median follow-up observation time is now 86 wks 
(range: 32–107 wks). Of 20 responders (14 PR, 6 CR), 10 have had durable responses per protocol 
assessment; their treatment durations and response characteristics are shown in Table 1. Responses 
were maintained in 2 pts (#5 and #6) after discontinuing nivolumab for >40 wks and in 1 pt (#7) after 
stopping due to toxicity. Eight pts with durable responses have received nivolumab for >1 yr, including 
7 pts who have been in response for >1.5 yrs. One pt (#2) with an initial CR experienced a relapse 43 
wks after treatment was discontinued, and achieved a second response (CR) after retreatment with 
nivolumab. Of the 10 remaining responders, 4 eventually progressed (time to progression [TTP] range: 
21.4–92 wks), 1 discontinued treatment due to toxicity with no PD within the 120-day follow-up period, 
and 5 discontinued nivolumab to undergo stem cell transplant (SCT; 4 allogeneic, 1 autologous) after 
achieving remission. Time to CR for all responders ranged from 3–88 wks after starting nivolumab, 
including 2 pts with initial PRs that converted to CRs with continued treatment. All 5 pts who 
proceeded to SCT had responded to nivolumab within 16 wks of starting treatment (4 PR, 1 CR). 
Ergänzende Informationen zu den Arzneistoffen für Priorisierung XXVII – HSS Onkologie Seite 10 von 12 
Three pts had a best overall response of SD (1 discontinued due to toxicity without documented PD 
within the 120-day follow-up period; 2 subsequently discontinued for PD [TTP: 15 and 15.3 wks, 
respectively]). Overall, 3 pts discontinued nivolumab due to adverse events (AEs; Grade 2 peripheral 
neuropathy, Grade 3 myelodysplastic syndrome, Grade 3 pancreatitis). Grade 1 or 2 immune-related 
AEs (IR-AEs) occurred in 4 of 10 pts and resolved without treatment in 2 pts. The incidence of IR-AEs 
did not increase with time on treatment. 
 
Conclusions 
In pts with R/R cHL, nivolumab was well tolerated and produced a high ORR. Responses occurred 
within 16 wks of nivolumab initiation in 15 of 20 pts. Early responses to nivolumab allowed 5 pts to 
proceed to SCT and lasted ≥1 yr in 7 of 10 pts who did not pursue SCT. One pt achieved CR again 
after retreatment with nivolumab when relapse occurred within 1 yr of discontinuing treatment following 
an initial CR. 
4 Leukemia 
4.1 Venetoclax (Venclexta™) in relapsed or refractory chronic 
lymphocytic leukaemia with 17p deletion 
Overview 
Drug Description 
is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an 
anti-apoptotic protein. 
Patient Indication 
venetoclax for relapsed or refractory del(17p) chronic lymphocytic 
leukaemia 
Incidence in 
Austria 
1,265 newly diagnosed per year (2012), 9.0 /100,000/year 
Ongoing Phase III NCT02756611 - until 2020 
Approval 
status for 
this 
indication 
EMA - 
FDA 
04/2016: for the treatment of patients with chronic lymphocytic leukemia 
(CLL) who have a chromosomal abnormality called 17p deletion and who 
have been treated with at least one prior therapy. 
Approval 
status for 
other 
indications 
EMA 
On 17 February 2016, orphan designation (EU/3/16/1617) was granted by 
the European Commission to Abbvie Ltd., United Kingdom, for venetoclax 
for the treatment of acute myeloid leukaemia. 
FDA - 
Costs - 
 
Phase II results  
The Lancet Published Online May 10, 2016 (Stilgenbauer et al.): “Venetoclax in relapsed or 
refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study” 
Background 
Deletion of chromosome 17p (del[17p]) in patients with chronic lymphocytic leukaemia confers very 
poor prognosis when treated with standard chemo-immunotherapy. Venetoclax is an oral small-
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molecule BCL2 inhibitor that induces chronic lymphocytic leukaemia cell apoptosis. In a previous first-
in-human study of venetoclax, 77% of patients with relapsed or refractory chronic lymphocytic 
leukaemia achieved an overall response. Here we aimed to assess the activity and safety of 
venetoclax monotherapy in patients with relapsed or refractory del(17p) chronic lymphocytic 
leukaemia. 
 
Methods 
In this phase 2, single-arm, multicentre study, we recruited patients aged 18 years and older with 
del(17p) relapsed or refractory chronic lymphocytic leukaemia (as defined by 2008 Modified 
International Workshop on Chronic Lymphocytic Leukemia guidelines) from 31 centres in the USA, 
Canada, UK, Germany, Poland, and Australia. Patients started once daily venetoclax with a weekly 
dose ramp-up schedule (20, 50, 100, 200, 400 mg) over 4–5 weeks. Patients were then given daily 
400 mg continuous dosing until disease progression or discontinuation for another reason. The 
primary endpoint was the proportion of patients achieving an overall response, assessed by an 
independent review committee. Activity and safety analyses included all patients who received at least 
one dose of study drug (per protocol). This study is registered with ClinicalTrials.gov, number 
NCT01889186. Follow-up is ongoing, and patients are still receiving treatment. 
 
Findings 
Between May 27, 2013, and June 27, 2014, 107 patients were enrolled into the study. At a median 
follow-up of 12·1 months (IQR 10·1–14·2), an overall response by independent review was achieved 
in 85 (79·4%; 95% CI 70·5–86·6) of 107 patients. The most common grade 3–4 adverse events were 
neutropenia (43 [40%]), infection (21 [20%]), anaemia (19 [18%]), and thrombocytopenia (16 [15%]). 
Serious adverse events occurred in 59 (55%) patients, irrespective of their relationship to treatment, 
with the most common (≥5% of patients) being pyrexia and autoimmune haemolytic anaemia (seven 
[7%] each), pneumonia (six [6%]), and febrile neutropenia (five [5%]). 11 patients died in the study 
within 30 days of the last dose of venetoclax; seven due to disease progression and four from an 
adverse event (none assessed as treatment related). 
 
Interpretation 
Results of this trial show that venetoclax monotherapy is active and well tolerated in patients with 
relapsed or refractory del(17p) chronic lymphocytic leukaemia, providing a new therapeutic option for 
this very poor prognosis population. Additionally, in view of the distinct mechanism-of-action of 
venetoclax, combinations or sequencing with other novel targeted agents should be investigated to 
further advance treatment of del(17p) chronic lymphocytic leukaemia. 
4.2 Inotuzumab ozogamicin versus standard therapy for acute 
lymphoblastic leukemia 
Overview 
Drug Description 
is an antibody–drug conjugate that consists of a cytotoxic moiety 
(derivative of calicheamicin) attached to a humanized monoclonal anti-
CD22 antibody 
Patient Indication inotuzumab ozogamicin in acute lymphoblastic leukemia 
Incidence in 
Austria 
1,265 newly diagnosed per year (2012), 9.0 /100,000/year 
Ongoing Phase III NCT01564784 until 07/2017 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
EMA 
On 7 June 2013, orphan designation (EU/3/13/1127) was granted by the 
European Commission to Pfizer Limited, United Kingdom, for inotuzumab 
ozogamicin for the treatment of B-cell acute lymphoblastic leukaemia. 
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indications 
FDA - 
Costs - 
 
Phase III results  
NEJM, published on June 12 2016, and updated on June 23, 2016 (Kantarjian et al.): 
“Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia” 
 
Background 
The prognosis for patients with acute lymphoblastic leukemia is poor. We sought to determine whether 
inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, results in better 
outcomes in patients with relapsed or refractory acute lymphoblastic leukemia than does standard 
therapy.  
 
Methods 
In this phase 3 trial, we randomly assigned adults with relapsed or refractory acute lymphoblastic 
leukemia to receive either inotuzumab ozogamicin (inotuzumab ozogamicin group) or standard 
intensive chemotherapy (standard-therapy group). The primary end points were complete remission 
(including complete remission with incomplete hematologic recovery) and overall survival.  
 
Results  
Of the 326 patients who underwent randomization, the first 218 (109 in each group) were included in 
the primary intention-to-treat analysis of complete remission. The rate of complete remission was 
significantly higher in the inotuzumab ozogamicin group than in the standard-therapy group (80.7% 
[95% confidence interval {CI}, 72.1 to 87.7] vs. 29.4% [95% CI, 21.0 to 38.8], P<0.001). Among the 
patients who had complete remission, a higher percentage in the inotuzumab ozogamicin group had 
results below the threshold for minimal residual disease (0.01% marrow blasts) (78.4% vs. 28.1%, 
P<0.001): the duration of remission was longer in the inotuzumab ozogamicin group (median, 4.6 
months [95% CI, 3.9 to 5.4] vs. 3.1 months [95% CI, 1.4 to 4.9]; hazard ratio, 0.55 [95% CI, 0.31 to 
0.96]; P=0.03). In the survival analysis, which included all 326 patients, progression-free survival was 
significantly longer in the inotuzumab ozogamicin group (median, 5.0 months [95% CI, 3.7 to 5.6] vs. 
1.8 months [95% CI, 1.5 to 2.2]; hazard ratio, 0.45 [97.5% CI, 0.34 to 0.61]; P<0.001); the median 
overall survival was 7.7 months (95% CI, 6.0 to 9.2) versus 6.7 months (95% CI, 4.9 to 8.3), and the 
hazard ratio was 0.77 (97.5% CI, 0.58 to 1.03) (P=0.04). In the safety population, the most frequent 
grade 3 or higher no hematologic adverse events with inotuzumab ozogamicin were liver-related. 
Veno-occlusive liver disease of any grade occurred in 15 patients (11%) who received inotuzumab 
ozogamicin and in 1 patient (1%) who received standard therapy. 
 
Conclusions 
The rate of complete remission was higher with inotuzumab ozogamicin than with standard therapy, 
and a higher percentage of patients in the inotuzumab ozogamicin group had results below the 
threshold for minimal residual disease. Both progression-free and overall survival was longer with 
inotuzumab ozogamicin. Veno-occlusive liver disease was a major adverse event associated with 
inotuzumab ozogamicin. (Funded by Pfizer; INO-VATE ALL ClinicalTrials.gov number, 
NCT01564784.) 
